CYP2D6 polymorphisms influence tamoxifen treatment outcomes in
Descrição
CYP2D6 polymorphisms and tamoxifen adverse effects - Video Abstract ID 126557
Frontiers Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer
Bioavailability and Pharmacokinetics of Endoxifen in Female Rats and Dogs: Evidence to Support the Use of Endoxifen to Overcome the Limitations of CYP2D6-Mediated Tamoxifen Metabolism
CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial - ScienceDirect
Simplistic representation of the main biotransformation of tamoxifen
Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen
Effects of Genetic Polymorphisms of Drug Metabolizing Enzymes and co‐Medications on Tamoxifen Metabolism in Black South African Women with Breast Cancer - Chiwambutsa - 2023 - Clinical Pharmacology & Therapeutics - Wiley Online Library
JPM, Free Full-Text
de
por adulto (o preço varia de acordo com o tamanho do grupo)
